- genetic engineeringa unit of Roche Holding Ltd RHHBYannounced that the phase 3 study IMbrave050 reached its primary endpoint of recurrence-free survival (RFS) at the pre-specified interim analysis.
- The study is evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as an adjuvant treatment after surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence.
- The Tecentriq combination demonstrated a statistically significant improvement in RFS in the intention-to-treat population of HCC patients at increased risk of recurrence after resection or ablation with curative intent compared to active surveillance.
- Overall survival data were immature at the interim analysis and follow-up will continue until the next analysis.
- The safety of Tecentriq and Avastin was consistent with the known safety profile of each therapeutic and the underlying disease.
- Results from the IMbrave050 study will be discussed with health authorities and presented at an upcoming medical meeting.
- The IMbrave050 study randomized 662 people.
- Genentech has an extensive development program for Tecentriq, alone and in combination, including multiple ongoing and planned Phase 3 studies in multiple lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.
- price action: RHHBY shares closed 0.45% lower at $39.73 on Wednesday.
- Photo via company
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
